References
- Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 1993;53:538-549
- Chen L, Chantra PK, Larsen LH, Barton P, Rohitopakarn M, Zhu EQ, et al. Imaging characteristics of malignant lesions of the male breast. Radiographics 2006;26:993-1006
- Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg 1990;125:210-214
- Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14: 20-26
- Burga AM, Fadare O, Lininger RA, Tavassoli FA. Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases. Virchows Arch 2006;449:507-512
- Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist 2005;10:471-479
- He M, Liu H, Jiang Y. A Case report of male occult breast cancer first manifesting as axillary lymph node metastasis with part of metastatic mucinous carcinoma. Medicine (Baltimore) 2015;94:e1038
- Sohn G, Son BH, Lee SJ, Kang EY, Jung SH, Cho SH, et al. Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: a nationwide retrospective study. J Surg Oncol 2014;110:270-274
- Leonard RC, Mansi JL, Keerie C, Yellowlees A, Crawford S, Benstead K, et al. A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('sprog' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the anglo-celtic cooperative group and ncrn. Ann Oncol 2015;26:2437-2441
- Hur SM, Cho DH, Lee SK, Choi MY, Bae SY, Koo MY, et al. Occult breast cancers manifesting as axillary lymph node metastasis in men: a two-case report. J Breast Cancer 2012; 15:359-363